STOCK TITAN

Bioasis to Attend and Present at Upcoming Industry Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

BIOASIS TECHNOLOGIES INC (OTCQB:BIOAF) announced its participation in the Sachs 5th Annual Neuroscience Innovation Forum, where Dr. Deborah Rathjen, CEO, will present on advancements in Alzheimer's Disease and dementia. The event will occur digitally from March 21-25, 2022. Bioasis is focused on developing its proprietary xB3™ platform technology aimed at delivering therapeutics across the blood-brain barrier to tackle CNS disorders, including brain cancers and neurodegenerative diseases. This reflects Bioasis's commitment to addressing critical medical needs in the field.

Positive
  • None.
Negative
  • None.

NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that Dr. Deborah Rathjen, Executive Chair and Chief Executive Officer of Bioasis will attend and present at the Sachs 5th Annual Neuroscience Innovation Forum Digital conference, including participation on a panel about the Latest Developments in AD & Dementia.

On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen, Ph.D.
Executive Chair of the Board
deborah@bioasis.us
+1.203.533.7082
Follow on:
Facebook
Instagram
LinkedIn
Twitter

BTI-E&P

About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. For more information about the Company, please visit www.bioasis.us.

Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact along with other statements containing the words “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts:

Deborah Rathjen, Ph.D., Executive Chair of the Board and CEO
deborah@bioasis.us
203-533-7082

Investor Contact:
Graeme Dick
Colwell Capital Corp.
graeme@colwellcapital.com
403-561-8989


FAQ

When is the Sachs 5th Annual Neuroscience Innovation Forum?

The Sachs 5th Annual Neuroscience Innovation Forum will take place from March 21-25, 2022.

Who is presenting on behalf of Bioasis at the forum?

Dr. Deborah Rathjen, the CEO of Bioasis, will present at the forum.

What technology is Bioasis developing?

Bioasis is developing the proprietary xB3™ platform technology for delivering therapeutics across the blood-brain barrier.

What medical areas does Bioasis focus on?

Bioasis focuses on treating CNS disorders, including brain cancers and neurodegenerative diseases.

What is the stock symbol for Bioasis Technologies Inc?

The stock symbol for Bioasis Technologies Inc is BIOAF.

BIOASIS TECHNOLOGIES INC

OTC:BIOAF

BIOAF Rankings

BIOAF Latest News

BIOAF Stock Data

476.48k
77.78M
2.05%
Biotechnology
Healthcare
Link
United States of America
New Haven